Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
China's population drops for 2nd year, with record low birth rateOlivia Munn's breast cancer diagnosis raising awareness for women to seek additional screeningChinese media levels Australian spy claimJapan's lunar craft lands successfully but can't generate solar powerKindergarten teacher in China poisoned classroom porridge in staff quarrelLabour's Rino Tirikatene retires from politicsDredging to deepen challenging boat entrance in WhakatāneChinese dissident artist Ai Weiwei protests possible extradition of Julian Assange in LondonDeath penalty for artist behind Kyoto anime fire, which killed 36Hong Kong man jailed 21 months for throwing eggs
2.5087s , 6496.5 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,Culture Channel news portal